Animal vaccines

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10 .sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered nonpathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine prarinfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier suitable for parenteral or intranasal administration, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml each of live attenuated canine parainfluenza virus and live attenuated canine adenovirus Type 2 in a physiologically acceptable carrier, each of said viruses being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered nonpathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.5 to about 10.sup.9 inactivated Bordetella bronchisepticus bacteria per ml and from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A vaccine useful in immunizing dogs against kennel cough comprising from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier suitable for parenteral or intranasal administration, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog at least 100 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by a sufficient number of serial passages in susceptible tissue culture until the virus is rendered non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by at least 15 serial passages in susceptible tissue culture to render the virus non-pathogenic without loss of immunogenicity.

A method of immunizing dogs against kennel cough which comprises parenterally or intranasally administering to a susceptible dog from about 10.sup.4 to about 10.sup.6 TCID.sub.50 per ml of live attenuated canine parainfluenza virus in a physiologically acceptable carrier, said virus being attenuated by from about 20 to about 45 serial passages in canine kidney tissue culture to render the virus non-pathogenic without loss of immunogenicity.